Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
MOMA Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Agenus Inc.
City of Hope Medical Center
National Cancer Institute (NCI)
Duke University
AstraZeneca
Memorial Sloan Kettering Cancer Center
Loma Linda University
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
Complement Theory Inc.
NeoTX Therapeutics Ltd.
Memorial Sloan Kettering Cancer Center
Pfizer
Institute of Cancer Research, United Kingdom
Massachusetts General Hospital
Vanderbilt-Ingram Cancer Center
Sensei Biotherapeutics, Inc.
University of Alabama at Birmingham
University College, London
OncoC4, Inc.
Memorial Sloan Kettering Cancer Center
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Carisma Therapeutics Inc
University of Toronto
NGM Biopharmaceuticals, Inc